Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Highly parallel characterization of IgG Fc binding interactions.

Boesch AW, Brown EP, Cheng HD, Ofori MO, Normandin E, Nigrovic PA, Alter G, Ackerman ME.

MAbs. 2014 Jul-Aug;6(4):915-27. doi: 10.4161/mabs.28808.

2.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
3.

Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.

Lu J, Sun PD.

Immunol Rev. 2015 Nov;268(1):192-200. doi: 10.1111/imr.12346. Review.

PMID:
26497521
4.

In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.

Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Rüger P, Reusch D.

PLoS One. 2015 Aug 12;10(8):e0134949. doi: 10.1371/journal.pone.0134949. eCollection 2015.

5.

Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.

Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):604-9. doi: 10.1073/pnas.0908590107. Epub 2009 Dec 18.

6.

Fcγ receptor pathways during active and passive immunization.

Bournazos S, Ravetch JV.

Immunol Rev. 2015 Nov;268(1):88-103. doi: 10.1111/imr.12343. Review.

PMID:
26497515
7.

Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.

Caaveiro JM, Kiyoshi M, Tsumoto K.

Immunol Rev. 2015 Nov;268(1):201-21. doi: 10.1111/imr.12365. Review.

PMID:
26497522
8.

Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.

Hayes JM, Frostell A, Cosgrave EF, Struwe WB, Potter O, Davey GP, Karlsson R, Anneren C, Rudd PM.

J Proteome Res. 2014 Dec 5;13(12):5471-85. doi: 10.1021/pr500414q. Epub 2014 Nov 11.

PMID:
25345863
9.

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV.

J Clin Invest. 2014 Feb;124(2):725-9. doi: 10.1172/JCI72676. Epub 2014 Jan 9.

10.

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1.

Nesspor TC, Raju TS, Chin CN, Vafa O, Brezski RJ.

J Mol Recognit. 2012 Mar;25(3):147-54. doi: 10.1002/jmr.2155.

PMID:
22407978
11.

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.

MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.

12.

Interaction sites on human IgG-Fc for FcgammaR: current models.

Jefferis R, Lund J.

Immunol Lett. 2002 Jun 3;82(1-2):57-65. Review.

PMID:
12008035
13.

Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors.

Radaev S, Sun PD.

J Biol Chem. 2001 May 11;276(19):16478-83. Epub 2001 Jan 31.

14.

Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding.

Subedi GP, Hanson QM, Barb AW.

Structure. 2014 Oct 7;22(10):1478-88. doi: 10.1016/j.str.2014.08.002. Epub 2014 Sep 4.

15.

Capture of the human IgG1 antibodies by protein A for the kinetic study of h-IgG/FcγR interaction using SPR-based biosensor technology.

Champion T, Beck A.

Methods Mol Biol. 2013;988:331-43. doi: 10.1007/978-1-62703-327-5_21.

PMID:
23475730
16.

Characterization and crystallization of soluble human Fc gamma receptor II (CD32) isoforms produced in insect cells.

Sondermann P, Jacob U, Kutscher C, Frey J.

Biochemistry. 1999 Jun 29;38(26):8469-77.

PMID:
10387093
17.

An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.

Borrok MJ, Mody N, Lu X, Kuhn ML, Wu H, Dall'Acqua WF, Tsui P.

J Pharm Sci. 2017 Apr;106(4):1008-1017. doi: 10.1016/j.xphs.2016.12.023. Epub 2017 Jan 3.

PMID:
28057542
18.

Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.

Namboodiri AM, Pandey JP.

Clin Exp Immunol. 2011 Dec;166(3):361-5. doi: 10.1111/j.1365-2249.2011.04477.x.

19.

Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.

Ju MS, Na JH, Yu YG, Kim JY, Jeong C, Jung ST.

Mol Immunol. 2015 Oct;67(2 Pt B):350-6. doi: 10.1016/j.molimm.2015.06.020. Epub 2015 Jul 4.

PMID:
26153451
20.

N-linked glycan structures of the human Fcγ receptors produced in NS0 cells.

Cosgrave EF, Struwe WB, Hayes JM, Harvey DJ, Wormald MR, Rudd PM.

J Proteome Res. 2013 Aug 2;12(8):3721-37. doi: 10.1021/pr400344h. Epub 2013 Jul 11.

PMID:
23777450

Supplemental Content

Support Center